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ABSTRACT: Animal models are eﬀective for assessing tumor
localization of nanosystems but diﬃcult to use for studying
penetration beyond the vasculature. Here, we have used well-
characterized HCT116 colorectal cancer spheroids to study
the eﬀect of nanoparticle (NP) physicochemical properties on
penetration and uptake. Incubation of spheroids with Hoechst
33342 resulted in a dye gradient, which facilitated
discrimination between the populations of cells in the core
and at the periphery of spheroids by ﬂow cytometry. This
approach was used to compare doxorubicin and liposomal
doxorubicin (Caelyx) and a range of model poly(styrene)
nanoparticles of diﬀerent sizes (30 nm, 50 nm, 100 nm) and with diﬀerent surface chemistries (50 nm uniform plain,
carboxylated, aminated and a range of NPs and polyethylene glycol modiﬁed NPs prepared from a promising new functionalized
biodegradable polymer (poly(glycerol-adipate), PGA). Unmodiﬁed poly(styrene) nanoparticles (30 nm/50 nm) were able to
penetrate to the core of HCT116 spheroids more eﬃciently than larger poly(styrene) nanoparticles (100 nm). Surprisingly,
penetration of 30 and 50 nm particles was as good as clinically relevant doxorubicin concentrations. However, penetration was
reduced with higher surface charge. PGA NPs of 100 nm showed similar penetration into spheroids as 50 nm poly(styrene)
nanoparticles, which may be related to polymer ﬂexibility. PEG surface modiﬁcation of polymeric particles signiﬁcantly
improved penetration into the spheroid core. The new model combining the use of spheroids Hoechst staining and ﬂow
cytometry was a useful model for assessing NP penetration and gives useful insights into the eﬀects of NPs’ physical properties
when designing nanomedicines.
There has been great interest in using nanoparticle systemsto deliver anticancer drugs into tumors as they oﬀer
advantages such as selective accumulation at the tumor site,
with potential for enhanced eﬃcacy and reduced toxicity
compared to conventional drug treatment. Much of the
justiﬁcation for the use of nanoparticles is based on the
enhanced permeability and retention eﬀect, which proposes
that macromolecules and nanoparticles accumulate in tumors
due to a leaky vasculature and absence of a lymphatic system.
Variation in vascular leakiness in diﬀerent types and diﬀerent
areas of the same tumor can lead to limited accumulation in
tumors and lowers the eﬀectiveness of the treatments.1 The
heterogeneous distribution in tumors is thought to be a reason
why Doxil and Abraxane, nanosystems which have been FDA-
approved for cancer, demonstrate disappointing treatment
beneﬁts in poorly vascularized tumors.2,3 However, this is just
the ﬁrst step of reaching the target cells, and penetration
through the tumor extracellular matrix (ECM) and uptake into
tumor cells is at least as important. There is a limited amount
of data in the literature on how the ECM impacts various
nanosystems, but there are several examples of poor
penetration into tumors resulting in poor performance of
these novel therapeutics.4−7
The ability of drug molecules and nanosystems to reach
their target cells may be aﬀected by the complex physiology of
the tissue. Tumors consist of cancer cells and supportive
stroma which includes an ECM bathed in an extra cellular
ﬂuid. The extracellular ﬂuid can constitute in excess of 20% of
the tumor volume.8 The ECM is a meshwork made of collagen
ﬁbers, proteoglycans, or glycosamino glycans such as
hyaluronic acid and heparan sulfate forming a highly viscous
and negatively charged barrier.9−11 These components are
thought to largely prevent convective ﬂow within the tumor
matrix, meaning that molecules move through the matrix by
diﬀusion, thus limiting the rate of movement of molecules and
nanomaterials through the tumor tissue.12−14 However, there
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are lower levels of proteoglycans and hyaluronate present
within tumors.8 Additionally, steric factors and electrostatic
interactions due to repulsion and binding to the ECM
components will inﬂuence the rate of movement.15,16 There
is, however, a need to develop a better understanding of how
these interactions aﬀect the delivery of drugs and nanosystems
into tumors and whether these delivery systems can be
optimized to minimize these eﬀects.
The current process for testing the eﬀectiveness of
nanosystems relies greatly on animal models. However, the
animal models that are readily available such as the human
tumor xenograft or genetically engineered mouse models are
technically diﬃcult, expensive, and time-consuming to use and
poorly representative of the clinical disease. Additionally, it is
more diﬃcult to achieve the resolution needed to see
penetration at the cellular and tissue level, and so these
models will be less useful for understanding and inappropriate
for mass screening of nanodelivery systems. If we are to
develop a rational design of nanoparticles (NPs), there is a
need for representative in vitro models and screening methods
that will allow the testing of penetrability of nanomedicines in
the early stages of the drug development process. While the in
vitro model should mimic the in vivo tumor microenvironment
as far as possible, it also should be simple and easy to
reproduce and analyze.17 We have chosen to work with 3D
human tumor spheroids as a model for solid tumors as they are
believed to more closely resemble the tumor microenviron-
ment.18−21 They have a 3D spatial arrangement with enhanced
cell to cell contact and the ability to form proliferative
gradients, hypoxia, and necrosis. Certain ECM components
were found to be expressed at high levels in 3D spheroids,
hence they have the potential to establish the penetration
barriers seen in vivo, thereby allowing us to study the
penetration, distribution, and uptake of nanoparticles within
these models.22−25 However, to date, there are limited
numbers of studies that employ tumor spheroids for the
evaluation of nanomedicines.
Although there is increasing evidence indicating that the
physicochemical properties of NPs such as size, charge, and
surface chemistry play a crucial role in their ability to penetrate
through the ECM, the eﬀect of these physicochemical
properties on penetration and uptake in representative tumor
models has not been examined systematically.2,15,26
In the present study, we have taken well characterized
human tumor spheroids and developed a convenient method-
ology to assess the penetration of nanoparticles into these
spheroids. We have examined the eﬀects of the size, surface,
and bulk characteristics of a range of NPs on the penetration
and cellular uptake into tumors. We have compared a typical
anticancer drug, doxorubicin (DOX), with a clinically available
liposomal doxorubicin with a size of ∼87 nm, Caelyx (a
poly(ethylene glycol)ated (PEGylated) liposomal formulation
of DOX also marketed as Doxil). We have used well
characterized poly(styrene) latices as model NPs to assess
the eﬀects of size and charge. Finally, we have employed a
range of NPs prepared from some new experimental
biodegradable polymers with diﬀerent acyl and polyethylene
glycol modiﬁcations to assess their transport properties in
spheroids. From these various results, we aim to identify the
features that facilitate penetration of the nanosystems into
cancer tissue, thereby leading to development of drug delivery
systems with improved therapeutic performance.
■ RESULTS
3D Spheroid Model. The HCT116 colorectal spheroids
used in this study were based on the methodology described by
Ivanov et al.25 and, as in the previous work with brain tumor
cells, formed tight spheroids at day 3 of the culture with a
deﬁned border. The spheroids had an average diameter of 430
μm (Figure 1 A) and were very reproducible with a coeﬃcient
of variation in spheroid diameter ≤ 6% (n = 6) on day three
after seeding. The variation in spheroids size between
independent plates on day 3 was CV ≤ 5%.
Further, the immunohistochemical analysis revealed that
spheroids consisted of layers of tightly packed, mainly viable
proliferating cells with no necrotic core or hypoxia present
(Figure 1A−C). Additionally, Alcian Blue staining showed the
presence of sulfated and carboxylated acid glycosaminoglycans
and sulfated and carboxylated sialomucins (Figure 1D).
Having glycosaminoglycans present in HCT116 spheroids
indicates the presence of an extracellular matrix and suggests
that they should present a similar penetration barrier to that
seen in vivo. While diﬀerent tumors may be expected to have a
range of diﬀerent absolute penetration characteristics, a model
containing the appropriate components should allow a realistic
comparison between the penetration characteristics of diﬀerent
types of particles.
Optimization of Flow Cytometry/Hoechst Method. A
qualitative picture of NP penetration can be obtained using
confocal microscopy imaging of spheroids. However, this
suﬀers from an increasing quenching of ﬂuorescence with
increasing depth from the spheroid surface, and it is tedious to
cut histological sections to derive data from the whole spheroid
routinely. In order to quantify the penetration and uptake of
NPs in a convenient and robust manner, we have adopted a
ﬂow cytometry analysis method using Hoechst 33342 dye. The
Hoechst dye is a nuclear stain which forms a noticeable
diﬀusion/consumption gradient as it diﬀuses through sphe-
roids. Therefore, at an appropriate concentration, the dye
Figure 1. Immunohistological assessment of HCT116 spheroid
microenvironment; 4 μm paraﬃn cross-section stained with (A)
haematoxylin and eosin showing spheroid morphology and
compaction; (B) proliferation marker Ki = 67, brown staining
(peroxidase) showing proliferating cells; (C) pimonidazole, a lack of
staining (brown) indicates absence of hypoxic regions; (D) Alcian
Blue/fast red showing strongly acidic sulfated mucosubstances, blue;
nuclei, pink to red; cytoplasm, pale pink. Scale bar 100 μm.
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stains cells at the periphery of the spheroid to a greater extent
than the cells within the core of the spheroid. The technique
was previously used by Durand et al. for the selection of
populations of cells with diﬀerent proliferative statuses in
spheroids after drug treatment and was found to be highly
sensitive and reproducible. The dye has also been employed in
vivo for localization of tissue near blood vessels.27
In the present work, we optimized Hoechst staining for
gradient formation by incubating HCT116 spheroids with
diﬀerent concentrations of the dye (Figure 2 A, B).
Concentration-dependent penetration was observed, with 0.1
μM dye concentration forming a ﬂuorescent gradient that,
following cell disaggregation and ﬂuorescence activated cell
sorter (FACS) analysis, could be divided into three concentric
segments based on the ﬂuorescence intensity of the cells.
Unstained cells (40% (±1%) of total cell population)
representing cells within the center of the spheroid; the
brightest 20% (±1%) of the total cell population representing
cells at the rim of spheroids and weakly stained cells located in
a middle segment between the center and the rim (40% (±1%)
of cell population; Figure 2C,D). (From calculations of
volumes of a sphere, the unstained core corresponds to an
inner radius of approximately 160 μm, the middle weakly
stained segment a ring of a further 40 μm depth, and the
brightly stained rim the outside 15 μm thickness of an average
spheroid.) Once the Hoechst concentration was selected, the
spheroids were incubated with ﬂuorescently labeled nano-
particles (2, 4, 6 and 24 h) and with the dye (4 h) to determine
time-dependent penetration and uptake of these nanoparticles
in HCT116 spheroids. The spheroids were dissociated into
individual cells, ﬁxed, and assayed by ﬂow cytometry. It should
be noted that as the cells are dissociated for the FACS
quantitation, we will detect only the particles which both
penetrate the spheroid and are taken up into cells.
Penetration and Uptake of Doxorubicin in HCT116
Spheroids. To compare the relative penetration of nano-
particles with a drug, DOX was chosen as a relevant marker.
DOX would be expected to behave similarly to Hoechst dye,
Figure 2. Concentration-dependent penetration of Hoechst in HCT116 spheroids incubated with 0.1 μM, 0.5 μM, 2 μM, and 10 μM of Hoechst
for 4 h (blue, nuclei stained with Hoechst). (A) Confocal images representing the degree of staining of spheroids at diﬀerent concentrations of
Hoechst in comparison with Bright ﬁeld views showing the extent of the spheroid. (B). FACS plots showing the distribution of HCT116 cells using
varying concentrations of Hoechst and representing the distribution of cells based on the degree of staining at each concentration. (C) FACS dot
plot of HCT116 spheroids stained with 0.1 μM Hoechst. The dye forms a diﬀusion gradient in spheroids that can be divided into three segments:
40% (±1%) unstained cell population representing the core, 20% (± 1%) brightest cells representing periphery, and 40% (±1%) weakly stained,
representing cells between the rim and core of spheroids.
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being a DNA-binding lipophilic molecule of similar molecular
weight. This makes it a particularly good example for
determining the penetration of a potent anticancer drug in
our model. Additionally, DOX is the drug component of the
nanoscale liposomal formulation Caelyx, so we can determine
the penetration of a clinically approved nanoparticulate
formulation of the same drug with well-described in vivo
properties in our model. Further, free DOX is ﬂuorescent,
which allows for easy detection via confocal microscopy and
FACS.
The penetration and distribution of free DOX were
evaluated in HCT116 spheroids after exposing the cells to
diﬀerent concentrations of the drug at 1 μg/mL and 10 μg/mL
for diﬀerent incubation periods, 4 and 24 h. These
concentrations were chosen to be relevant to the clinical
context, as the plasma mean concentration of free DOX in
patients receiving a single intravenous dose of DOX solution is
0.2 μg/mL after 1 h and 0.1 μg/mL after 4 h, after which it
reaches a plateau and remains at this level for 24 h.28,29 Thus,
in our study, the lower concentration of the free DOX (1 μg/
mL) is closer to the drug concentration achieved clinically than
the higher concentration of 10 μg/mL. The results were
quantiﬁed by the FACS/Hoechst method in Figure 3A−E.
Two diﬀerent measures have been used to assess penetration
into spheroids: ﬁrst, the percentage of cells with a label, which
counts any cell with a level of dye/drug above the background
showing the extent of penetration, and second, the mean
Figure 3. Penetration and uptake of doxorubicin and Caelyx in HCT116 spheroids. (A) Time-dependent penetration of DOX (1 μg/mL and 10
μg/mL) and Caelyx (providing 75 μg/mL of free DOX) in HCT116 spheroids by FACS. (B, C) Percentage of cells reached by the free DOX and
Caelyx to diﬀerent regions in spheroids after 4 and 24 h incubation time. (D, E) MFI plots showing accumulation of amounts of DOX and Caelyx
per cell across the core, middle, and rim in HCT116 spheroids after 4 and 24 h incubation (****, ***, **, and * indicate p < 0.0001, p < 0.001, p <
0.01, and p < 0.05, respectively). Control values are background ﬂuorescence of untreated cells.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.9b00136
Bioconjugate Chem. 2019, 30, 1371−1384
1374
ﬂuorescence intensity (MFI) of cells, which is related to the
average uptake of dye/drug in a particular population of cells.
Penetration of free DOX into HCT116 spheroids was time-
dependent as well as concentration-dependent. At the lower
dose of 1 μg/mL, the free DOX was detectable in around 50%
of cells within the ﬁrst 2 h, steadily increasing up to 80% of
cells after 6 h incubation time and then increasing more
gradually to reach 90% of cells in the spheroid by 24 h.
At the earlier time point (4 h), many more cells in the outer
parts of the spheroid had taken up the drug than in the core of
the spheroid (Figure 3B and C). A much higher number of
cells taking up the drug toward the center of the spheroid was
observed after 24 h of incubation. On the basis of the MFI, it is
clear that the uptake of DOX across spheroids at 1 μg/mL is
low and decreases toward the core (Figures 3D and E).
Penetration and Uptake of Doxorubicin in HCT116
Spheroids. By increasing concentration of the free DOX to 10
μg/mL, signiﬁcantly faster delivery into the core of spheroid
was achieved, with over 80% cells reached after only 2 h of
incubation. The drug was associated with more than 90% of
cells after 6 h of incubation. The uptake of free DOX at 10 μg/
mL in the cells across the spheroid was still observed to be
lower in the core at the early time point, 4 h, with a similar
percentage of cells in each region having taken up DOX after
24 h. The higher concentration of DOX resulted in much
higher accumulation of the drug in cells than the lower dose as
quantiﬁed in Figure 3A−E. Additional original data of the
FACS dot plots are given in Supporting Information Figure S1.
As a comparison, penetration and uptake of a liposomal
formulation of DOX has been evaluated for the ability to
deliver DOX to the colorectal spheroids. The formulation was
tested at a concentration providing 75 μg/mL with respect to
DOX, which is higher than the mean concentration of ∼25 μg/
mL achieved in plasma in patients receiving a single dose of
Caelyx. The higher concentration was necessary in the study
due to the technical inability to detect ﬂuorescence in cells at a
lower concentration. As seen in Figure 3A, the penetration
proﬁle of DOX via this nanoformulation was also found to be
time-dependent. The diﬀusion of DOX as Caelyx in the
HCT116 spheroid was very slow with less than 10% of cells
containing DOX after 2 h incubation and 85% after 24 h
incubation. As in the case of the free DOX, there was a large
diﬀerence in the percentage of cells taking up Caelyx as
measured by DOX ﬂuorescence within the diﬀerent spheroid
Figure 4. Size-dependent penetration of NPs into spheroids. (A) Confocal images of frozen sections (sections = 20 μm thickness) of HCT116
spheroids incubated with 30, 50, and 100 nm unmodiﬁed poly(styrene) nanoparticles (75 μg/mL). Scale bar 100 μm. Images processed to
normalize ﬂuorescence intensity by applying LUT ﬁre in ImageJ software. (B) Time-dependent penetration of NPs in spheroids by FACS/Hoechst
method. (C) Distribution of NPs in spheroids 4 h. (D) Distribution of NPs in spheroids 24 h. (E) Accumulation of nanoparticles in HCT116
spheroids measured by the MFI of nanoparticles after 4 h and (F) 24 h incubation. Control values are background ﬂuorescence of untreated cells.
(****, ***, **, and * indicate p < 0.0001, p < 0.001, p < 0.01, and p < 0.05, respectively).
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regions at the 4 h time points, whereas a more similar uptake of
Caelyx was seen across all regions of spheroid after 24 h
(Figure 3B,C). The results also demonstrated that penetration
of Caelyx and uptake into the cells of the spheroid was
signiﬁcantly slower and with much lower accumulation of the
drug than that of the free DOX, even without accounting for
the much higher dose of DOX in Caelyx used in this
experiment (Figure 3D,E). The high level of Dox in Caelyx
used may raise concerns about the potential toxicity of this
higher concentration of drug in the formulation and its eﬀects
on the model. However, we saw no evidence for this eﬀect,
either in terms of the cell numbers from the spheroid available
for analysis or the quality of cells seen by FACS parameters,
and the size of the spheroids did not noticeably decrease over
the longer time period (a key measure of toxicity).25 The lack
of toxicity probably relates to the slower penetration and
uptake of Caelyx as described above.
Eﬀect of Nanoparticle Size on Penetration in
Spheroids. To examine the eﬀect of size and surface
chemistry of NPs on traﬃcking into spheroids, poly(styrene)
NPs were employed as model particles as they are available in a
range of diﬀerent sizes and with versatile surfaces, thus
allowing for comparative study. The eﬀect of the size of NPs
on the penetration into HCT116 spheroids was evaluated by
using 30, 50, and 100 nm uniform plain poly(styrene) latices
[see Supporting Information Tables S1 and S2 for a summary
of NP characteristics]. The size-dependent penetration and
localization of NPs are qualitatively displayed by confocal
images of 20 μm thick spheroid sections in Figure 4A and
quantiﬁed by the FACS/Hoechst method in Figure 4B. In both
the confocal microscopy images and in the FACS data, the
Figure 5. (A) Inﬂuence of NP surface charge on penetration of NPs into spheroids. Confocal images of frozen sections (sections = 20 μm) of
HCT116 spheroids incubated with 50 nm of unmodiﬁed, aminated, and carboxylated poly(styrene) nanoparticles. Images processed to normalize
ﬂuorescence intensity by applying LUT ﬁre based on the ﬂuorescent intensity in ImageJ software. (B) Time-dependent penetration of NPs in
spheroids. (C) Distribution of NPs in spheroids. (D) Distribution of NPs in spheroids after 24 h. (E) Accumulation of nanoparticles in HCT116
spheroids measured by the MFI of nanoparticles after 4 h and (F) 24 h incubation. Control values are background ﬂuorescence of untreated cells
(****, ***, **, and * indicates p < 0.0001, p < 0.001, p < 0.01, and p < 0.05, respectively).
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ﬂuorescence has been normalized between diﬀerent systems
(Supporting Information Figure S2 shows raw FACS data
obtained in the dot plot format).
Small 30 nm NPs and 50 nm NPs were taken up in over 70%
and 80% of cells, respectively, within the ﬁrst 2 h of incubation,
increasing to >90% of cells in the spheroid after a 6 h
incubation. However, in the case of larger 100 nm nano-
particles, a diﬀerent penetration proﬁle was observed. Less
than 10% of cells contained 100 nm NPs after 2 h of
incubation, which further increased to a total of just 22% of
cells after a 24 h incubation (Figure 4B).
Further, 30 and 50 nm nanoparticles were distributed evenly
between the diﬀerent concentric cell population segments
based on Hoechst staining with ∼80% of cells in the core
segment of the spheroids taking up dye (Figure 4C,D).
However, the 100 nm NPs were strongly associated with the
periphery of spheroids with no signiﬁcant penetration achieved
in the core of spheroids even after the 24 h incubation period.
The results obtained by FACS correlate well with the results
obtained by confocal imaging. The level of nanoparticle
accumulation in the spheroids was investigated using the MFI
normalized between the diﬀerent NPs by designating a 50 nm
NP sample as equal to 1 and applying an adjustment factor to
the remaining NPs by use of ratiometric results. Figure 4E
shows the uptake of 30 and 50 nm NPs in spheroids after 4 h
incubation times. The plot shows a similar accumulation
proﬁle of the 30 and 50 nm particles, with slightly higher cell
uptake achieved by 30 nm NPs. No signiﬁcant diﬀerence in the
amount of NPs uptake between the core, middle, and
periphery of the spheroid was observed.
In Figure 4F, the accumulation proﬁle for these NPs is
presented after 24 h of incubation. It can be seen that while the
MFI levels of 50 nm NPs remain similar to the ones observed
after 4 h of incubation, the MFI of 30 nm increased
considerably. This suggests that 50 nm NPs reached maximum
accumulation in cells across the spheroid after 4 h of
Figure 6. (A) Time-dependent penetration of PGA NPs in spheroids by FACS/Hoechst method. (B) Distribution of PGA NPs in spheroids after 4
h. (C) Distribution of PGA NPs in spheroids after 24 h. (D) Accumulation of PGA nanoparticles in HCT116 spheroids measured by the MFI of
nanoparticles after 4 h of incubation and (E) after 24 h. The diﬀerence in MFI between the data was normalized by designating the PGA C18 NPs
sample as equal to 1 and applying that adjustment factor to the remaining NPs by use of ratiometric results. Concentration of NPs = 75 μg/mL.
Control values are background ﬂuorescence of untreated cells (****, ***, **, and * indicate p < 0.0001, p < 0.001, p < 0.01, and p < 0.05,
respectively).
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.9b00136
Bioconjugate Chem. 2019, 30, 1371−1384
1377
incubation while 30 nm NPs continued to accumulate over a
24 h period. The MFI levels of 100 nm NPs were not
investigated since these NPs do not penetrate far enough to
accumulate in cells located deeper in the spheroid. Uniform
uptake was observed for 30 and 50 nm NPs across the core,
middle, and periphery of the spheroid after 24 h.
Eﬀect of the Surface Charge of NPs on Penetration
and Distribution in Spheroids. Next, we investigated the
eﬀect of nanoparticles with the same size of 50 nm but
diﬀerent surface charges: positively charged aminated and
negatively charged carboxylated poly(styrene) nanoparticles in
comparison to the unmodiﬁed plain poly(styrene) NPs on
their ability to penetrate through spheroids. These more
hydrophilic NPs were used as purchased and characterized by
us before use (see Supporting Information Table S2).
When comparing these NPs, marked eﬀects of the surface
charge on penetration were observed. In the results by confocal
microscopy, only 50 nm unmodiﬁed NPs were detectable
within the core after 4 h of incubation while aminated 50 nm
NPs showed preferential association with the periphery of
spheroids. The 50 nm carboxylated nanoparticles were not
taken up at a detectable level at this time. FACS conﬁrmed that
the penetration of the 50 nm unmodiﬁed nanoparticles into
HCT116 spheroids was signiﬁcantly faster and higher than that
achieved by 50 nm aminated NPs (2×) or 50 nm carboxylated
NPs (8×) after 4 h of incubation (Figure 5A,B; Supporting
Information Figure S3 shows raw FACS data in dot plot
format).
Eﬀect of the Surface Charge of NPs on Penetration
and Distribution in Spheroids. The penetration and uptake
of 50 nm aminated NPs was found to be much slower and
more time dependent than 50 nm unmodiﬁed NPs. The
percent of cell uptake remained at <40% until 6 h of
incubation. The percentage cells with detectable levels of NPs
continued to increase, reaching ∼80% of cells after 24 h.
Despite the overall high percentage of cell association of 50 nm
aminated nanoparticles after 24 h, the distribution proﬁle
reveals signiﬁcantly lower penetration and uptake in the core of
spheroids compared to the outer layers after 24 h (Figure
5C,D).
The amount of cell uptake after 4 h of incubation as
determined by MFI revealed a high uptake of 50 nm amine
NPs in the rim of spheroids compared to the middle and core
and also compared to plain NPs. At 24 h, these diﬀerences
became more pronounced (Figure 5E and F).
Time Dependent Penetration of PGA and PGA-C18
NPs in HCT116 Spheroids. NPs were prepared using a
solvent displacement method and were characterized for size
and charge by DLS and zeta potential. The results showed that
all formulations had a comparable mean diameter in the range
of 109−117 nm when measured in deionized water and
displayed a zeta potential around −30 in 10 mM HEPES
similar to that of the plain poly(styrene) latices (for further
details of PGA NP properties, see Supporting Information
Tables S3 and S4).
Fast penetration of PGA NPs was observed with 80% cell
association achieved after 2 h of incubation (Figure 6A−C).
Signiﬁcantly slower penetration for PGA-C18 NPs was
observed than for PGA NPs with 30% cell association achieved
after 2 h. The addition of a PEG group to PGA-C18 NPs
signiﬁcantly improved their penetration to a level similar to
that of PGA alone or PGA−PEG (Supporting Information
Figure S4 shows raw FACS data obtained in the dot plot
format).
PGA NPs in HCT116 spheroids showed a greater
preferential accumulation of NPs at the periphery than the
middle or core (Figure 6D). NPs continued to accumulate
with time in all parts of the spheroid. PEGylated PGA-C18
NPs showed signiﬁcantly higher cell uptake in the cells at the
rim of spheroids than other PGA NPs after both 4 h and 24 h
incubation times (Figure 6E).
■ DISCUSSION
In the present study, a ﬂow cytometry method utilizing a
gradient of Hoechst staining as marker of cell position was
optimized and successfully employed for quantitative analysis
of penetration and distribution of diﬀerent drugs and
nanosystems in HCT116 spheroids. Only nanoparticles taken
up into cells are detected, as nanoparticles still outside the cells
will be lost on disaggregation. Previous work by us suggests
that the great majority of NPs penetrating into spheroids are
taken up by the cells;30 however, there may be a small number
of therapeutics which function at or bind to a non-
endocytosable cell surface receptor which could not be tested
in this model.
When considering the penetration of drug delivery systems
into tumors, there are a number of diﬀerent ways in which
drugs and nanoparticles may penetrate into tumors. Drugs can
usually diﬀuse and partition, so it is possible for drugs to easily
enter cells as well as pass through the extracellular matrix by
processes of diﬀusion and convection. NPs are not expected to
pass across membranes but to be taken up into cells by
endocytic processes and to be more restricted in passage
through the ECM because of their size, the expected eﬀects of
size on diﬀusion, and a more restricted passage due to ECM
porosity. Binding to charged ECM constituents and cell
surfaces may also aﬀect rates of transport and endocytosis. This
study aimed to investigate some of these parameters using our
new method.
It would be expected that the penetration of larger
nanoparticles into tumor tissue may be less good than that
of low molecular weight drugs, so the clinically relevant drug
DOX and its clinically available liposomal counterpart Caelyx
were investigated ﬁrst to give some baselines for further
comparisons. The results indicate that penetration of these
systems was time and concentration dependent in HCT116
spheroids. A direct comparison with the Caelyx liposomal drug
delivery system showed that penetration and uptake of Caelyx
was considerably less eﬀective than free DOX even after 24 h.
This was not a surprising result considering that diﬀusion is
inversely related to molecular weight. In vivo studies have also
indicated that penetration of Caelyx into tumors is restricted.31
This suggests that the model we have developed mirrors at
least some characteristics of in vivo studies.
This account of liposome penetration is also similar to that
of another HCT116 3D cell model where cells were seeded
into hydrogel nested artiﬁcial cancer masses and left to mature
for 7 days. In this latter model, both liposomes and micelles of
<100 nm diameter also penetrated less well than free Dox.32
Next, we examined a number of other nanoparticle based
systems to develop a better mechanistic understanding of the
factors inﬂuencing nanoparticle penetration and uptake. First,
we investigated the eﬀects of both size and surface character-
istics of model poly(styrene) nanoparticles on the penetration
in spheroids. Our results showed that smaller nanoparticles (30
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and 50 nm) showed greater penetration and accumulation in
the core of HCT116 spheroids when compared to the larger
(100 nm) nanoparticles. These results support our observa-
tions with the liposomal DOX (Caelyx) which appear to show
a penetration somewhere between that of 50 and 100 nm
poly(styrene) NPs and thus consistent with their size (∼87
nm)
Our results are also consistent with the outcomes of previous
in vivo and in vitro studies. Tang et al. compared the
penetration abilities of 50 and 200 nm camptothecin-silica
nanoparticle conjugates in the EL4 mouse T-lymphocyte
tumor models in vivo and ex vivo and found higher penetration,
accumulation, and internalization of the 50 nm nanoparticles
in comparison to 200 nm particles that localized at the surface
of tumors only.2 These results suggest that the extracellular
space together with the ECM matrix has a ﬁnite size restriction
on nanoparticle penetration. It has been suggested that smaller
nanoparticles are capable of diﬀusing through pores between
the collagen ﬁbrils, which have been measured to reach 20−40
nm in compact tumors and up to 75−130 nm in poorly
organized tumors.1433 This theory has been supported by
previous studies which found that improved penetration of
several therapeutic systems in solid tumors was achieved after
the disruption of the ECM by the use of protease enzymes,
collagenase, hyaluronidase, or drugs such as losartan.5,13
However, it is still not clear how nanoparticle size relates to
tumor penetration and cellular uptake. For instance, a study by
Huang et al. found that for gold particles with a size below
approximately 15 nm, there was better penetration than for
larger particles.34 Others also reported a diﬀerence in
penetration capabilities between dendrimers with diameters
of 2 and 4 nm/7 nm with the smallest showing better
penetration than the 7 nm particle.35 On the other hand, our
results have demonstrated that in the present model particles
up to 50 nm can successfully penetrate the tumor spheroids,
and there is little diﬀerence in penetration characteristics
compared to 30 nm NPs. These diﬀerences in penetration
related to size reported in the literature may depend on the
particular tumor model used for the study and diﬀerences in
penetration mechanisms and factors aﬀecting them.
The penetration of the 30 and 50 nm NPs were superior to
that of DOX 1 μg/mL and similar to that of DOX 10 μg/mL.
This is somewhat surprising as diﬀusion is inversely propor-
tional to molecular weight, which suggests that larger
nanoparticles would diﬀuse much more slowly than low
molecular weight drugs.
Studies on the polysaccharide components of ECM suggest
that at the concentrations present in ECM, they have an
exclusion eﬀect producing a colloid rich−water poor phase and
a water rich−colloid poor phase, so that in terms of transport,
larger molecules equilibrate faster than smaller molecules.
ECM thus acts like a gel ﬁltration chromatography column.9
Our results showing longer times for accumulation of smaller
drug molecules at the center of the spheroid in comparison to
larger NPs which penetrated and accumulated in cells across
the spheroid much faster ﬁt well with these theories. In more
recent work by Bao et al., it was proposed that liposomes of
larger size and near neutral surface chemistry have decreased
interactions with surrounding cells and ECM, and their
movement is mediated by convection.36 Jain et al. have also
suggested that small molecules travel by diﬀusion, which is
very restricted through the interstitial space; however, larger
molecules (up to ECM pore size) can take advantage of
movement by convection.8 This implies that nanosystems with
a small enough diameter and appropriate surface charge could
penetrate into a tumor easily and be retained there over time.37
Although penetration of drugs through tissue is believed to
be largely through the ECM, it will also be dependent on other
factors such as binding to cells and tissue components, uptake
into cells, and metabolism of the drugs.5,38 In fact, the amount
of both drug and NPs which are taken up and retained in cells
strongly indicates that the process of cellular uptake would
compete with penetration through the spheroid. The uptake of
drugs and that of nanoparticles into cells are very diﬀerent
processes. For a drug like DOX, which readily diﬀuses across
membranes and binds to DNA, there would be a strong
equilibrium in favor of uptake and binding to DNA, whereas
for NPs, which are taken up by the slower process of
endocytosis, the balance is more likely to be in favor of further
penetration into the spheroid, further advantaging the NPs in
addition to any size exclusion eﬀects. In considering whether
DOX penetration may be limited by the amount of DOX
bound to DNA in cells, some simple calculations have been
carried out (see Supporting Information: Calculations on DOX
Penetration into Spheroids). On the basis of the amount of
DOX bound to cells at IC50, if all the cells in the spheroid
bound the expected amount of DNA, it would only account for
about 1% of the DOX present in the well. However, the
volume of the spheroid is only about 0.02% of the volume of
the well, so the rate of diﬀusion of DOX to the cell may be a
rate limiting step in comparison to the rate of uptake of DOX
into the outer cells of the spheroid, thus reducing the rate of
penetration. This explanation would be supported by our data
showing that a 10× higher concentration of DOX readily
penetrated the spheroid.
We also observed that penetration of the 50 nm poly-
(styrene) nanoparticles was strongly inﬂuenced by their surface
characteristics. This suggests that other mechanisms in
addition to size play a crucial role in the penetration and
uptake process of nanoparticles. Indeed, it was proposed that
charged components of ECM restrict the diﬀusion of positively
and negatively charged particles due to electrostatic attraction
and binding.16 We have thus investigated the inﬂuence of the
surface charge of the nanoparticles using NPs with the same 50
nm size but diﬀerent surface charges: positively charged
aminated NPs and negatively charged carboxylated NPs. These
charged NPs are also more hydrophilic than the unmodiﬁed
NPs. Our results show that penetration of these particles was
strongly dependent on surface characteristics: whereas
unmodiﬁed 50 nm nanoparticles were capable of penetration
into the center of the spheroid (>200 μm depth), the
negatively charged carboxylated NPs were incapable of
penetrating further than one cell diameter from the rim. At a
simple level, it could be argued that this exclusion from
entering the spheroids is probably due to negative electrostatic
repulsion from the negatively charged components of the ECM
toward the negatively charged surface of both the spheroid and
the cell surfaces. In our study, both plain and carboxylated
nanoparticles had the same zeta potential in the HEPES buﬀer
(−32 mV), and both became slightly negative −6 ± 0.7 and
−9 ± 0.8, respectively, in RPMI-1640 medium supplemented
with fetal bovine serum (FBS), conditions which were used for
the studies. Despite similar characteristics shown by the zeta
potential, the nanoparticles behaved very diﬀerently in the
biological environment, thus aﬀecting their ability to penetrate
and accumulate in the spheroids. This is likely due to the
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adsorption of a protein corona on the nanoparticle surface,
which is shown by the increased size of the NPs by DLS when
incubated in a medium plus FBS (See Supporting Information
Table S2). Diﬀerent surfaces can result in adsorption of
diﬀerent serum components, which may have diﬀerent eﬀects
on NPs penetration and uptake but which are not deﬁned at
present in the context of spheroid models.39
The aminated NPs achieved a higher uptake into cells than
carboxylated NPs, presumably due to interactions with
negatively charged plasma membrane proteins on the cell
surface.8,16 However, their penetration through the spheroid
was slow and limited to the outer cell layers of the spheroid,
∼30−50 μm depth from the surface. This may be partly due to
a “binding site eﬀect” with the negatively charged ECM
components, which hindered further diﬀusion. However,
because of the increased cellular uptake of these positively
charged NPs both in 2D and in 3D culture, it may be that the
uptake of NPs into cells provides a larger barrier to penetration
of these particles further into the spheroid similar to the
binding site eﬀect seen for penetration of tumor associated
antibodies,26,40,41 but in this case due to a less speciﬁc
interaction. These results suggest that in vivo, these particles
could deliver a high therapeutic dose to the most accessible
cells but that cells deeper within the tumor may receive
subtherapeutic drug concentrations, especially if the NPs are
only present in the leaky vasculature for shorter periods. The
penetration of smaller, slightly negative unmodiﬁed NPs was
shown to penetrate easily into the core of spheroids, thus
systems with this characteristic should be a better choice for
cancer treatment.
To investigate a wider range of diﬀerent nanoparticle
properties, a series of novel biodegradable poly(glycerol
adipate) (PGA) polymers which oﬀer promising, new materials
for NP fabrication were also tested for their penetration ability
in 3D spheroids.42−46 PGA has on average one terminal
carboxyl group per chain, so it is expected to have some surface
hydrophilic character, and this is reﬂected in the negative zeta
potential of these nanoparticles (see Supporting Information
Table S4).
The results showed that unmodiﬁed PGA NPs of
approximately 100 nm diameter were able to penetrate to
the core of the spheroids after only 2 h of incubation, reaching
90% of the cells. However, when the PGA polymer was
modiﬁed with oleate (C18) moieties, the resulting NPs
showed signiﬁcantly slower penetration into spheroids and
restricted distribution across all regions of the spheroids. The
size and charge of those two types of NPs were comparable,
which indicates that other physicochemical features inﬂuenced
the behavior of these NPs. By modifying the PGA via partial
esteriﬁcation of the pendant hydroxyl group with the acid
chloride of fatty acids, a material with very diﬀerent
characteristics and composition is produced. It was shown
through measurement of the contact angle that the hydro-
phobicity of PGA increased with increased substitution and
length of acyl chains. Further, PGA substituted with C18
groups resulted in a semi crystalline character.47,30 Mackenzie
et al. found in computational studies that when this polymer is
used for NP formulation, the C18 groups arrange themselves
toward the inside of the nanoparticle.48 This indicates that the
hydrophobicity on the surface of the nanoparticle should not
be aﬀected signiﬁcantly. We thus hypothesize that diﬀerences
in softness/ﬂexibility of these polymeric nanoparticles could be
responsible for their altered penetration behavior. The
unsubstituted PGA polymer has a Tg much below room
temperature (Tg −30 °C), thus at body temperature, it exists in
a liquid-like state, i.e., it should form soft and ﬂexible
nanosystems.47 However, an increase of substitution of PGA
with C18 groups was shown to increase the Tg values due to a
higher fatty acid chain interaction and high steric hindrance
among polymer chains. This led to a higher rigidity of NPs47
(Supporting Information Table S5 shows measured thermal
properties and contact angles of PGA polymers). As already
noted, model poly(styrene) NPs of comparable size have a
penetration restricted to only 20% of the cell at the periphery
of the spheroids (Supporting Information Figure S5). Poly-
(styrene) is a hard plastic which has a glass transition
temperature (Tg) of ∼90 °C, so at body temperature this
material is in its glassy state, forming hard and rigid NPs. Thus,
the slower penetration abilities of PGA-C18 NPs and
poly(styrene) NPs could be a result of lower ﬂexibility in
comparison to unsubstituted PGA NPs (see Supporting
Information Figure S5 for a direct comparison of poly(styrene)
and PGA nanoparticle penetration). We hypothesize that the
more ﬂexible PGA systems are capable of deforming to squeeze
through restricted spaces between the ECM ﬁbers, providing
more eﬃcient penetration than the rigid NPs which end up
being trapped in the ECM pores, restricting their diﬀusion.
This hypothesis is in agreement with published observations
on diﬀusion through a 2% agarose gel where semiﬂexible
macromolecules were able to penetrate more eﬃciently
through the gel than rigid spherical systems of the same
hydrodynamic radius.3,49,50
The use of PEGylated-PGA nanoparticles was also
investigated. PEG is a hydrophilic and neutral molecule
which is often attached to the surface of liposomes and NPs.
The steric eﬀects and ﬂexibility of the surface PEG layer reduce
interactions of these systems with blood proteins, opsonins,
and macrophages allowing for a longer circulation time.51 By
conjugating the PEG to unsubstituted PGA and PGA-C18, it
was found that the resulting nanoparticles were capable of
eﬃcient penetration into the core of spheroids within a short
time frame (2−6 h) and continued to accumulate up to 24 h.
In particular, the addition of PEG to PGA-C18 signiﬁcantly
improved the penetration and accumulation of the system in
spheroids. The presence of PEG on the surface of nanosystems
is thought to reduce electrostatic interactions with ECM
components thereby improving their diﬀusion.52−54 There is
very little diﬀerence between the surface charge of the
PEGylated and non-PEGylated PGA-C18 NPs, but the
presence of PEG may have had an eﬀect on a variety of
possible interactions between the NP surface and ECM,
including those mediated by the presence of a protein corona.
This is in agreement with previous studies which investigated
the eﬀect of the addition of PEG to charged nanoparticles in
diﬀerent ECM matrices and in mucus and found an improved
penetration as a result.52,55 Surface PEGylation of NPs > 100
nm was also shown to facilitate diﬀusion in the brain
extracellular space.54,56 In the case of PGA-C18, the
penetration may have been further assisted by the eﬀect of
PEGylation of the polymer on the reduction of Tg and
increased ﬂexibility of the nanoparticle compared to non-
PEGylated PGA-C18.
Diﬀerent density and MW of PEG may also be a factor in
achieving the maximal penetration into the tumor; however,
this was not investigated in the present work.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.9b00136
Bioconjugate Chem. 2019, 30, 1371−1384
1380
While the present study gives us a good idea of the relative
performance of diﬀerent types of NPs, this is still a ﬁrst step
toward understanding how to design more successful delivery
systems for tumors. Diﬀerent tumors will have diﬀerent
combinations of host cells and tumor cells with diﬀerent
properties which are likely to aﬀect both ECM and rates of
endocytosis. Developing diﬀerent models with diﬀerent tumor
cell types and in combination with host cells, e.g., ﬁbroblasts
and immune cells will further enhance the picture of how NPs
penetrate tumors. It is noted, however, that cell cultures are
relatively homogeneous cell populations, whereas in tumors
the tumor cell heterogeneity may well play a further part in
penetration, so further models with multiple cell types will be
useful in extending our understanding of nanoparticle
penetration into various types of tumors.
■ CONCLUSION
We have taken well-characterized HCT116 spheroids as a
model system to compare the penetration of diﬀerent NPs into
tumors and investigated the eﬀect of diﬀerent composition and
physicochemical features. We have employed Hoechst dye
together with FACS to facilitate a quantitative assessment of
penetration and distribution of nanoparticles in the spheroids.
The method is highly sensitive and robust when compared to
other methods used for the detection of nanoparticles within
the core of spheroids such as microscopy or sequential
trypsinisation.27,57,58 It allows for fast detection of as few as 5−
10 NPs per cell and provides a promising in vitro screening
method for assessing nanoparticles in the early stages of their
development.24
Our results highlight the need to control physicochemical
features of nanoparticles such as size and surface charge when
designing nanomedicines in order to achieve the best delivery
of therapeutic agents into tumors.
■ METHODS
Materials. HCT 116 cells were obtained from the CRN
NCI-60 cell bank initiative, Cancer Biology, Division of Cancer
and Stem Cells, School of Medicine, University of Nottingham.
Ki-67, BrdU, horseradish peroxidase rabbit-antimouse secon-
dary antibody, and diaminobenzidin (DAB) were obtained
from Pathology Products, Dako UK Ltd. (Ely, UK).
Pimonidazole (Hypoxyprobe-1) was purchased from Hypo-
xyprobe, Inc. (Burlington, USA). Dulbecco’s Phosphate
Buﬀered Saline (PBS), L-glutamine solution (2 mM), RPMI-
1640, Accutase Solution, Agarose, DPX mounting medium,
and fast red solution were obtained from Sigma-Aldrich
(Dorset, UK). Foetal Bovine Serum (FBS) solution was
supplied by Invitrogen (Paisley, UK). Trypsin-EDTA was
obtained from Gibco, Life Technologies Ltd. (Paisley, UK).
Ultralow attachment 96-well round-bottom plates were
obtained from Corning (UK). Paraformaldehyde solution
(4%) and Alcian Blue were purchased from Alfa Aesar, a
Johnson Matthey Company (Heysham, UK). Tissue-embed-
ding cassettes were sourced from Simport (Beloeil, Canada).
SuperFrost glass and poly-L-lysine coated slides were obtained
from Menzel (Braunschweig, Germany). Vinyl specimen mold,
CryomoldH, and Tissue-TekH O.C.T. compound were
obtained from Tissue-Tek and Sakura Finetek (CA).
Haematoxylin and Eosin were from Raymond Lamb (East-
bourne, UK). The Annexin V-FITC Apoptosis Detection Kit
was purchased from eBioscience (Hatﬁeld, UK). Hoechst
33342 (NucBlue Live ReadyProbes Reagent) was sourced
from Life Technologies Ltd. (Paisley, UK). Doxorubicin
(Adriamycin, Pﬁzer, UK) was provided by Cancer Biology
Unit, Division of Cancer and Stem Cells University of
Nottingham. PEGylated Liposomal doxorubicin hydrochloride
(CAELYX) was purchased from Janssen (High Wycombe,
UK). Rhodamine B isothiocyanate (RBITC) was purchased
from Sigma-Aldrich (Poole, UK). Fluorescently labeled
uniform plain poly(styrene) nanoparticles of sizes 30, 50,
100, 300, and 50 nm aminated and 50 nm carboxylated
poly(styrene) nanoparticles were purchased from Magsphere
Inc. (US) and used without further modiﬁcation. Sephadex G-
25 in PD-10 desalting columns were from GE Healthcare’s Life
Sciences solutions (Little Chalfont, UK).
Preparation of PGA NPS. Polymer synthesis: Poly-
(glycerol adipate) (PGA) was synthesized enzymatically from
divinyl adipate and glycerol in DMF in the presence of
Novozyme 435 at 50 °C, as described by Taresco et al.36 PGA
C18 was prepared by substitution of hydroxyl groups of PGA
by reﬂux with acyl chloride in THF in the presence of pyridine.
Full details for this synthesis can be found in Taresco et al.39
PEGylation of Polymers. In order to couple PEG chains
(Mw = 2000 Da) to either PGA or PGAC18, a simple and
consistent Steglich esteriﬁcation was adopted by applying the
same reaction conditions. Thus, the example (PGA−PEG)
below can be applied to both the PGA−PEGylated
modiﬁcations. Typically, PGA (1 g/0.1 mmol) and DMAP
(0.015 mmol) were added to anhydrous THF (20 mL) at
room temperature in a round-bottom ﬂask under magnetic
stirring until complete dissolution. In particular, since it is
exclusively the end group of the PGA chain that takes part in
this reaction, the whole molecular weight of the polymer was
taken into consideration for any stoichiometry. A second
solution was prepared by dissolving 0.15 mmol of dicyclohexyl
carbodiimide and 0.15 mmol of PEG in THF (20 mL). The
dicyclohexyl carbodiimide-PEG solution was poured into the
polymer. The reaction was allowed to stir overnight. The
resulting dicyclohexylurea was removed by centrifugation, and
the supernatant solvent was removed under reduced pressure.
The modiﬁed polymer was redissolved in THF and
precipitated twice in cold MeOH. The residual material was
dried under reduced pressure to a stable weight.
Nanoparticles from PGA and PGA derivatives were prepared
by a nanoprecipitation method using acetone as a solvent as
previously described by Meng et al.43 Brieﬂy, the polymer (5
mg) was dissolved in acetone (2 mL) containing RBITC (2
mg/mL), and the solution was added dropwise into HEPES
buﬀer (5 mL). The mixture was left stirring overnight at room
temperature to allow for acetone to evaporate. The
unincorporated ﬂuorescent dye from ﬂuorescently labeled
NPs was removed by Sephadex PD-10 Desalting Column using
gravity ﬂow according to the manufacturer protocol.
Characterization of Nanoparticles. Zetasizer Nano-ZS
(Malvern Instruments, Worcestershire, UK) was used to
measure size distribution, Z potential, and polydispersity
index of nanoparticles. Experiments were conducted at 25 °C
after diluting the nanoparticles to 200 μg/mL in 10 mM
HEPES, RPMI-1640 medium, and RPMI-1640 medium
supplemented with 10% FBS.
Spheroid Culture. Ultra low attachment 96-well round-
bottom plates were employed for the culturing of spheroids.
Cells grown as a monolayer were detached using trypsin and
then centrifuged, and the cell number was counted using a
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hemocytometer. Spheroids were seeded by diluting the single-
cell suspensions in a RPMI-1640 medium with 10% FBS and
104 cells per mL were added at a constant volume (200 μL)
per well in 96-well ultra low attachment plates. Six wells
containing the same concentration of cells were created for the
experiments. The plates were centrifuged at 100g for 4 min.
The medium (150 μL) was removed on days 3 and 5 and
replaced with fresh medium.
Growth of HCT116 Spheroids. Spheroids were imaged
daily for 7 days using a Nikon Eclipse Ti microscope with a 4×
objective (Nikon limited, Surrey, UK). The pictures were
analyzed using image J and a macro written by Ivanov et al.35
The diameter and volume of spheroids were determined by
measuring their cross-sectional area.
Immunochemical Analysis of HCT116 Spheroids.
Prior to processing, spheroids were ﬁxed using paraformalde-
hyde solution (4%) in PBS for 1 h. Prior to wax embedding,
ﬁxed spheroids were transferred to the top of a solidiﬁed
agarose gel (1.5%, 200 μL) in 1.5 mL microcentrifuge tubes.
The spheroids were allowed to sediment on top of the agarose
gel, and supernatant was removed by gentle aspiration. Warm
liquid agarose (1% w/v in sterile water, ∼100 μL) was gently
added on top of the spheroids and left to set. Once solidiﬁed,
the tip of the microcentrifuge tube was excised using a blade,
and the piece of the agarose containing the spheroids was
transferred into tissue embedding cassettes and were processed
using a routine paraﬃn embedding technique (Leica EG1160,
Milton Keynes, UK). Sections of 4 μm were cut using a
microtome (Leica RM2135), placed on Super Frost glass
slides. The prepared slides were stained with Haematoxylin
and Eosin (H&E) and Alcian Blue (pH 2.5)/fast red as per
standard protocol. Ki-67 was used for staining of proliferating
cells; mouse-antihuman Ki-67 clone MIB-1 (46 mg/L; 1:200 in
PBS) was used followed by incubation with horseradish
peroxidase-rabbit-antimouse secondary antibody (1.3 g/L) at
1:300 dilution followed by DAB staining. Citric acid buﬀer at
pH 6 and 98 °C for 30 min was used for antigen retrieval.
Hypoxia detection was performed by using pimonidazole
hypochloride. Spheroids were incubated for 2 h with PIMO at
a 100 μM ﬁnal concentration in the media. The spheroids were
then ﬁxed and processed for frozen sections. Pimonidazole
adducts were detected by incubating sections with ﬂuorescein
isothiocyanate-conjugated MAb1 (monoclonal antibody as
provided by the supplier, 1:300) for 2 h at 37 °C. The sections
were counterstained with hematoxylin. The slides were
coverslipped with DPX and air-dried overnight, and spheroid
sections were assessed by microscopy (Leica DMLB).
Penetration and Uptake of Nanoparticles into
Spheroid Model. Spheroids were grown on ultra low
attachment plates for 3 days to allow for compaction prior
to use for the penetration and uptake studies. On day 3 of the
culture, the media were removed from the wells and replaced
with media (150 μL) containing NPs (75 μg/mL) or DOX (1
μg/mL or 10 μg/mL or 75 μg/mL as Caelyx) and were left to
incubate for 2−24 h. Four hours prior to the end of the
incubation, Hoechst was added to the wells (ﬁnal concen-
tration in the well = 0.1 μM) and was left to incubate. At the
end of the incubation, the spheroids were washed three times
with PBS and ﬁxed with 4% paraformaldehyde for 1 h then
processed for frozen sections.
Evaluating the Penetration of Fluorescent Poly-
(styrene) Nanoparticles by Confocal Microscopy. After
ﬁxation, spheroids were incubated in 30% sucrose in PBS
overnight at 4 °C. Spheroids were transferred onto a vinyl
specimen mold. The remaining sucrose solution was aspirated,
and the tissue-TekH O.C.T. compound was gently poured
over the spheroids. The spheroids were then submerged in an
isopentane bath cooled by dry ice and cut into 20-μm-thick
sections using a cryostat microtome. The sections were
mounted onto superfrost glass slides and were gently immersed
in PBS to remove the remaining OCT compound. Sub-
sequently, the frozen sections of spheroids incubated with NPs
were examined by confocal microscopy (laser 538) and by
image J software. The sections from the middle of a minimum
of two independent spheroids per experiment were selected
based on the degree of Hoechst staining, and the experiment
was repeated twice. In image J, the images were pseudocolored
with mask LUT “ﬁre” that reﬂects diﬀerences in intensity of
the nanoparticles within spheroids.
Evaluating the Penetration and Uptake of Fluores-
cent Poly(styrene) Nanoparticles by Flow Cytometry.
After incubation of spheroids with NPs for 2, 4, 6, and 24 h
and Hoechst 33342 (0.1 μM) for 4 h, the spheroids were
transferred into 15 mL Falcon conical tubes and washed twice
with PBS (1 mL). Accutase (1 mL, 400−600 units/mL) was
then added, and the tubes incubated at 37 °C for 3 min with
agitation. The dissociation of spheroids was aided by
mechanical pipetting. The spheroids were then centrifuged,
ﬁxed, and washed in PBS and subsequently analyzed by ﬂow
cytometry (MoFlo Astrios Cell sorter, Beckman Coulter). A
blue laser at 355−488 nm and a yellow/green laser at 488−664
nm were used as an excitation source for the detection of
Hoechst and nanoparticle ﬂuorescence, respectively. Samples
were analyzed with the Kaluza Analysis 1.3 Software. Cells-
only control was used to set the threshold for cells without
NPs. Cells were divided into three cell populations
representing the rim, middle, and core of spheroid based on
the intensity of staining with Hoechst, 20%, 40%, and 40% of
total cells, respectively. (As the divisions are created manually,
there is a small variation in the sizes of the diﬀerent divisions.)
The diﬀerence in mean ﬂuorescence intensity (MFI) between
the data was normalized by designating one NP in a set to
equal 1 and applying that adjustment factor to remaining NPs
by use of ratiometric results.
Statistical Analysis. Unless otherwise stated, all data are
shown as mean ± standard deviation (SD; n = number of
spheroids per experiment). One way analysis of variance
(ANOVA) was applied for comparison of three or more group
means. A P value of < 0.05 was considered statistically
signiﬁcant. ****, ***, **, and * display p < 0.0001, p < 0.001,
p < 0.01, and p < 0.05, respectively. GraphPad Prism 6
software was used for data analysis.
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